SEC Form SC 13G/A filed

2/8/21 10:31:28 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SRPT alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 4 SAREPTA THERAPEUTICS INC COMMON STOCK Cusip #803607100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #803607100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 645,534 Item 6: 0 Item 7: 6,115,228 Item 8: 0 Item 9: 6,115,228 Item 11: 7.741% Item 12: HC Cusip #803607100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 6,115,228 Item 8: 0 Item 9: 6,115,228 Item 11: 7.741% Item 12: IN Item 1(a). Name of Issuer: SAREPTA THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 215 FIRST STREET, SUITE 415 CAMBRIDGE, MA 02142 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 803607100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 6,115,228 (b) Percent of Class: 7.741% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 645,534 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 6,115,228 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of SAREPTA THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of SAREPTA THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 5, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 5, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of SAREPTA THERAPEUTICS INC at December 31, 2020. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $SRPT alert in real time by email

Recent Analyst Ratings for

$SRPT

Date	Price Target	Rating	Analyst
5/8/2025	$50.00	Outperform → In-line	Evercore ISI
4/11/2025	$115.00	Overweight	Wells Fargo
4/2/2025	$75.00	Sell → Neutral	H.C. Wainwright
3/31/2025	$161.00 → $87.00	Outperform → Sector Perform	RBC Capital Mkts
2/11/2025	$136.00	Hold	Deutsche Bank
11/27/2024	$205.00 → $202.00	Buy	Needham
11/25/2024	$80.00	Sell	H.C. Wainwright
11/7/2024	$152.00 → $167.00	Neutral → Overweight	Cantor Fitzgerald

More analyst ratings

SEC Form SC 13G/A filed

Chat with this insight

Recent Analyst Ratings for $SRPT

$SRPT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Nicaise Claude exercised 9,746 shares at a strike of $25.18 and sold $248,203 worth of shares (2,491 units at $99.64), increasing direct ownership by 35% to 27,812 units (SEC Form 4)

Director Boor Kathryn Jean was granted 2,383 shares, increasing direct ownership by 41% to 8,263 units (SEC Form 4)

Director Connelly Deirdre P was granted 2,383 shares, increasing direct ownership by 84% to 5,225 units (SEC Form 4)

$SRPT Financials

Live finance-specific insights

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

$SRPT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

$SRPT Leadership Updates

Live Leadership Updates

$SRPT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

Sarepta Therapeutics Set to Join S&P MidCap 400

Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

SEC Form SC 13G filed by Sarepta Therapeutics Inc.

SEC Form SC 13G/A filed by Sarepta Therapeutics Inc. (Amendment)

$SRPT SEC Filings

SEC Form 10-Q filed by Sarepta Therapeutics Inc.

SEC Form DEFA14A filed by Sarepta Therapeutics Inc.

SEC Form DEF 14A filed by Sarepta Therapeutics Inc.

$SRPT Press Releases

Fastest customizable press release news feed in the world

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

$SRPT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

Barry Richard bought $3,940,500 worth of shares (50,000 units at $78.81) (SEC Form 4)

Ingram Douglas S bought $2,001,800 worth of shares (25,225 units at $79.36), increasing direct ownership by 7% to 390,307 units (SEC Form 4)

$SRPT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Sarepta Therapeutics downgraded by Evercore ISI with a new price target

Wells Fargo initiated coverage on Sarepta Therapeutics with a new price target

Sarepta Therapeutics upgraded by H.C. Wainwright with a new price target

Recent Analyst Ratings for
$SRPT

$SRPT
Insider Trading

$SRPT
Financials

$SRPT
FDA approvals

$SRPT
Leadership Updates

$SRPT
Large Ownership Changes

$SRPT
SEC Filings

$SRPT
Press Releases

$SRPT
Insider Purchases

$SRPT
Analyst Ratings